Consumer medicine information

Juliet-35 ED

Cyproterone acetate + Ethinylestradiol

BRAND INFORMATION

Brand name

Juliet-35 ED

Active ingredient

Cyproterone acetate + Ethinylestradiol

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Juliet-35 ED.

JULIET®-35 ED

JULIET®-35 ED


 Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.


 1. Why am I using JULIET®-35 ED?

JULIET®-35 ED contains the active ingredient cyproterone acetate and ethinylestradiol.

JULIET®-35 ED is used for treatment of signs of androgenization in women.

For more information, see Section 1. Why am I using JULIET®-35 ED? in the full CMI.

 2. What should I know before I use JULIET®-35 ED?

Do not use if you have ever had an allergic reaction to Juliet or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or if breastfeeding.

For more information, see Section 2. What should I know before I use JULIET®-35 ED? in the full CMI.

 3. What if I am taking other medicines?

Some medicines may interfere with JULIET®-35 ED and affect how it works.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

 4. How do I use JULIET®-35 ED?

Take one tablet daily at about the same time every day. Take your first tablet from the red area on the blister pack corresponding to the day of the week. Follow the direction of the arrows on the blister pack until all the tablets have been taken. Follow the instructions provided and use JULIET®-35 ED until your doctor tells you to stop

More instructions can be found in Section 4. How do I use JULIET®-35 ED? in the full CMI.

 5. What should I know while using JULIET®-35 ED?

Things you should do
  • Remind any doctor, dentist or pharmacist you visit and if you are going to have surgery, tell the surgeon or anesthetist beforehand that you are using JULIET®-35 ED
  • If you are about to have any blood tests, tell your doctor that you are taking this medicine.
  • Stop taking Juliet-35 ED and see your doctor immediately or go to the Emergency Department at your nearest hospital if you notice any of the signs detailed in section 5. What should I know while using JULIET®-35 ED?
  • Consult your doctor immediately if you become pregnant or develop high blood pressure or unexpected bleeding/vomit or have severe diarrhea or if you plan to air travel for greater than 4 hours
Things you should not do
  • Do not stop taking your medicine or change the dosage without checking with your doctor. You may become pregnant if you are not using any other contraceptive and you stop taking Juliet-35 ED, or do not take a tablet every day
Looking after your medicine
  • Keep your tablets in a cool dry place where the temperature stays below 25°C.

For more information, see Section 5. What should I know while using JULIET®? in the full CMI.

 6. Are there any side effects?
  • If you notice possible signs/concerned about increased risk of blood clots, stop taking Juliet-35 ED and consult your doctor immediately
  • Breast Cancer/Cervical Cancer has been diagnosed more often in women who take pill than who do not take
  • Increased Risk of Meningioma is reported in women who take high doses (25 mg and above) of cyproterone acetate

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.


JULIET®-35 ED (Joo·lee.ET Ee.Dee)

Active ingredient(s): [cyproterone acetate and ethinylestradiol]


 Consumer Medicine Information (CMI)

This leaflet provides important information about using Juliet-35 ED. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using JULIET®-35 ED.

Where to find information in this leaflet:

1. Why am I using JULIET®?
2. What should I know before I use JULIET®?
3. What if I am taking other medicines?
4. How do I use JULIET®?
5. What should I know while using JULIET®?
6. Are there any side effects?
7. Product details

1. Why am I using JULIET®-35 ED?

JULIET®-35 ED contains the active ingredients cyproterone acetate and ethinylestradiol.

JULIET® is used for the treatment of signs of physical male characteristics caused by the male sex hormone, androgen, produced by in women in small amounts (androgenisation), such as:

  • severe acne where other treatments have not been successful
  • for excessive growth of facial or body hair (known as hirsutism) of a mild to moderate degree, where no underlying cause has been found.

JULIET-35 ED can also be used as a contraceptive to prevent pregnancy in women who are taking it for the treatment of signs of physical male characteristics as described above.

JULIET-35 ED contains a progestogen and an estrogen hormone, and therefore works similarly to the combined oral contraceptive birth control pill, also known as ‘the Pill’. It should not be used in combination with another hormonal contraceptive.

While taking JULIET-35 ED you may also experience the following benefits:

  • more regular and lighter periods – potentially resulting in a decreased risk in anemia (iron deficiency)
  • a decrease in period pain
  • reduction of greasiness in skin and hair.

Some conditions such as pelvic inflammatory disease, ovarian cysts, ectopic pregnancy (where the foetus is carried outside of your womb), lumpy breasts and cancer of the uterus (womb) and ovaries may be less common in women taking Juliet-35 ED.

Ask your doctor if you have any questions about why this medicine has been prescribed for you.

Your doctor may have prescribed it for another reason.

2. What should I know before I use JULIET®-35 ED?

Warnings

Do not use JULIET®-35 ED if:

  • you are allergic to cyproterone acetate and/or ethinylestradiol (the active ingredients in Juliet-35 ED) and any of the ingredients listed at the end of this leaflet.
  • Always check the ingredients to make sure you can use this medicine.

Some of the symptoms of an allergic reaction may include:

  • shortness of breath
  • wheezing or difficulty in breathing
  • swelling of the face, lips, tongue or other parts of the body
  • rash, itching or hives on the skin.

JULIET-35 ED is not for use in men.

Do not take Juliet-35 ED if you are taking antiviral medicines which contain glecaprevir, pibrentasvir, sofosbuvir, velpatasvir, voxilaprevir, ombitasvir, paritaprevir, or dasabuvir, and combinations of these. These antiviral medicines are used to treat chronic (long-term) hepatitis C (an infectious disease that affects the liver, caused by the hepatitis C virus).

Do not take Juliet-35 ED if you have, or have had, a blood clot in:

  • the blood vessels of the legs (deep vein thrombosis - DVT)
  • the lungs (pulmonary embolism - PE)
  • the heart (heart attack)
  • the brain (stroke)
  • other parts of the body.

Do not take Juliet-35 ED if you are concerned about or have an increased risk of blood clots.

Blood clots are rare. Very occasionally blood clots may cause serious permanent disability and may even be fatal.

All combined oral contraceptive pills, including Juliet-35 ED, increase the risk of having a blood clot. However, the risk of having a blood clot when taking Juliet-35 ED is less than the risk of having a blood clot during pregnancy.

Do not take Juliet-35 ED if you are concerned about an increased risk of blood clots because of age or smoking.

The risk of having a heart attack or stroke increases as you get older. It also increases if you smoke. You should stop smoking when taking Juliet-35 ED, especially if you are older than 35 years of age.

Do not take Juliet-35 ED if you have, or have had:

  • blood clots in your legs
  • any blood clotting disorders such as Protein C deficiency, Protein S deficiency, Leiden Factor V mutation, Antithrombin III deficiency or other inherited blood clotting conditions.
  • A confirmed blood test showing:
    - increased levels of homocysteine
    - antiphospholipid antibodies (APLAs) e.g. anticardiolipin-antibodies and lupus anticoagulant. These may increase your risk for blood clots or pregnancy losses (miscarriage).
  • major surgery after which you have not been able to move around for a period of time
  • angina (chest pain)
  • a mini stroke (also known as TIA or transient ischemic attack)
  • migraine, where you have also had problems with seeing, speaking or had weakness or numbness in any part of your body
  • high risk of blood clots due to conditions such as diabetes with blood vessel damage, severe high blood pressure or severe high or low level of fats in your blood
  • pancreatitis (an inflammation of the pancreas) associated with high levels of fatty substances in your blood
  • severe liver disease and your liver function has not returned to normal
  • a benign or malignant liver tumour
  • cancer that may grow under the influence of sex hormones (e.g. of the breast or the genital organs)
  • meningioma or history of meningioma (a generally benign tumour of the tissue layer between the brain and the skull)
  • unexplained vaginal bleeding.

If any of these conditions appear for the first time while using Juliet-35 ED, stop taking it at once and tell your doctor. In the meantime, use non-hormonal (barrier) methods of contraception (such as condoms or a diaphragm).

Do not take Juliet-35 ED if you are using another hormonal contraceptive.

Do not take this medicine if you are pregnant or think you might be pregnant.

Do not breast-feed if you are taking this medicine.

Do not give this medicine to a child.

Do not take this medicine after the expiry date printed on the pack and blister. The expiry date is printed on the carton and on each blister after “EXP” (e.g. 11 18 refers to November 2018). The expiry date refers to the last day of that month. If it has expired return it to your pharmacist for disposal.

Do not take this medicine if the packaging is torn or shows signs of tampering.

If the packaging is damaged, return it to your pharmacist for disposal.

If you are not sure whether you should start taking this medicine, talk to your doctor.

Check with your doctor if you:

  • you smoke
  • you, or anyone in your immediate family has had blood clots in the legs (DVT), or lungs (PE), a heart attack, a stroke, breast cancer or high cholesterol.
  • have any other medical conditions like
    - diabetes
    - high blood pressure
    - heart valve disorders or certain heart rhythm disorders
    - migraine
    - cancer
    - polycystic ovary syndrome, a hormonal condition which can cause menstrual irregularity and excess hair growth
    - hyperhomocysteinaemia, a condition characterised by high levels of the amino acid homocysteine in the blood
    - severe high or low levels of fats in the blood.
  • take any medicines for any other condition

Ask your doctor to check if you:

  • are overweight
  • have any hereditary or acquired conditions that may make it more likely for you to get blood clots
  • have high cholesterol or triglycerides
  • have liver disease
  • have jaundice (yellowing of the skin) and/or pruritus (itching of the skin) related to cholestasis (condition in which the flow of bile from the liver stops or slows)
  • have gall bladder disease
  • have Crohn's disease or ulcerative colitis (chronic inflammatory bowel disease)
  • have systemic lupus erythematosus (SLE – a disease affecting the skin all over the body)
  • have haemolytic uraemic syndrome (HUS – a disorder of blood coagulation causing failure of the kidneys)
  • have sickle cell disease
  • have a condition that occurred for the first time, or worsened during pregnancy or previous use of sex hormones (e.g. hearing loss, a metabolic disease called porphyria, a skin disease called herpes gestationis, a neurological disease called Sydenham's chorea)
  • have chloasma (yellowish-brown pigmentation patches on the skin, particularly of the face) – if so, avoid exposure to the sun or ultraviolet radiation
  • have hereditary angio-oedema – you should see your doctor immediately if you experience symptoms of angio-oedema, such as swollen face, tongue and/or pharynx and/or difficulty swallowing or hives together with difficulty in breathing.

If any of the above conditions appear for the first time, recur, or worsen while taking Juliet-35 ED, you should tell your doctor.

Juliet-35 ED contains lactose.

If you have an intolerance to some sugars, tell your doctor before you start taking Juliet-35 ED.

If you have not told your doctor about any of the above, tell him/her before you start taking Juliet-35 ED.

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Check with your doctor if you are pregnant or intend to become pregnant.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

If you do not wish to fall pregnant, you should use additional barrier contraceptive precautions (e.g. condoms or a diaphragm) when you stop taking Juliet-35 ED.

If you are considering becoming pregnant, it is recommended that you begin taking a vitamin supplement containing folic acid. It is best that you start taking folic acid tablets before you stop taking Juliet-35 ED and not stop until your doctor advises this. Ask your doctor or pharmacist about suitable supplements. It is both safe and recommended that you take folic acid during pregnancy

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins, or supplements that you buy without a prescription from your pharmacy, supermarket, or health food shop.

Some medicines and Juliet-35 ED may interfere with each other. These include:

Medicines used to treat:Examples of drugs:
TuberculosisRifampicin, Rifabutin
EpilepsyPhenytoin,
Primidone,
Barbiturates (e.g. Phenobarbitone),
Carbamazepine,
Oxcarbazepine,
Topiramate,
Felbamate,
Lamotrigine
HIVRitonavir or Nevirapine
Hepatitis C Virus (HCV)Boceprevir, telaprevir, glecaprevir, pibrentasvir, ombitasvir, paritaprevir, dasabuvir
AntibioticsClarithromycin,
Erythromycin
Fungal infectionsKetoconazole and Griseofulvin
ImmunosuppressantCiclosporin
High blood pressure, chest pain and/or irregular heartbeatsDiltiazem, Verapamil
Anti-inflammatory medicine to treat painEtoricoxib
Medicines used to relax the bodyTizanidine, Melatonin or Midazolam
Medicine that helps with breathingTheophylline
Herbal medicines containing St John's Wort
Grapefruit juice

These medicines may be affected by Juliet-35 ED or may affect how well it works. Your doctor may need to alter the dose of your medicine or prescribe a different medicine.

Some medicines

  • can have an influence on the blood levels of Juliet-35 ED
  • can make it less effective in preventing pregnancy or
  • can cause unexpected bleeding.

You may need to use additional barrier methods of contraception (such as condoms or a diaphragm) while you are taking any of these medicines with Juliet-35 ED and for some time after stopping them.

Your doctor will be able to tell you how long you will need to use additional contraceptive methods.

Your doctor and pharmacist have more information on medicines that you need to be careful with or avoid while taking this medicine

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect Juliet-35 ED.

4. How do I use JULIET®?

How much to take/use?

  • Take one tablet daily at about the same time every day. You must take Juliet-35 ED every day regardless of how often you have sex. This will also help you remember when to take it.
  • Follow the instructions provided and use Juliet-35 ED until your doctor tells you to stop.
  • You may have to take Juliet-35 ED for at least 6 months before you see an improvement in your condition. The length of treatment depends on the severity of the condition and how well it responds to treatment.
  • You may be advised by your doctor to stop Juliet-35 ED 3 to 4 months after your symptoms have completely resolved.
  • You should have regular check-ups with your doctor to determine how long to keep taking Juliet-35 ED.

Swallow the tablet whole with a full glass of water. It does not matter if you take it before or after food.

Each blister pack is marked with the day of the week.

Take your first tablet from the red area on the blister pack corresponding to the day of the week.

Follow the direction of the arrows on the blister pack until all the tablets have been taken.

A period should begin 2-3 days after starting to take the white inactive tablets (last row) and may not have finished before the next pack is started.

Always start a new blister pack on the same day of the week as your previous pack.

Taking Juliet-35 ED for the first time

If you are starting Juliet-35 ED after a natural cycle, and you have not used a hormonal contraceptive in the past month, start on the first day of your period, i.e. on the first day of your menstrual bleeding.

You must also use additional barrier contraceptive precautions (e.g. condoms or a cap or diaphragm plus spermicide) for the first 14 days of tablet-taking when having intercourse.

Your doctor will advise you when to start if you:

  • are taking Juliet-35 ED after having a baby
  • have had a miscarriage or an abortion.

Changing from another contraceptive

Changing from a combined oral contraceptive:

Start taking Juliet-35 ED on the day after taking the last active tablet in your previous Pill pack. Bleeding may not occur until the end of the first pack of Juliet-35ED.

If you are not sure which were the active/inactive tablets in your previous Pill pack, ask your doctor or pharmacist.

Your previous Pill pack may have different colour tablets to those of Juliet-35 ED.

Changing from a vaginal ring:

Start taking Juliet-35 ED on the day of removal of the last vaginal ring.

Changing from a progestogen-only pill (‘minipill’):

Stop taking the minipill on any day and start taking Juliet-35 ED at the same time the day after you took your last minipill.

You must also use additional barrier contraceptive precautions (e.g. condoms or a cap or diaphragm plus spermicide) for the first 14 days of tablet-taking when having intercourse.

When to take Juliet-35 ED

  • Juliet-35 ED should be at the same time every day.

If you forget to use Juliet-35 ED

Juliet-35 ED should be used regularly at the same time each day. If you miss your dose at the usual time and take the missing tablet within 12 hours of missing it, you should still be protected against pregnancy.

If you are more than 12 hours late follow these detailed instructions:

For Juliet-35 ED to be most effective, beige active tablets need to be taken uninterrupted for 7 days.

If you have been taking the beige active tablets for 7 uninterrupted days and miss a beige active tablet, take the missed tablet as soon as you remember, then go back to taking your medicine as you would normally, even if this means taking two tablets in one day at the same time.
You will not need to use additional barrier contraceptive precautions.

The chance of pregnancy after missing a beige active tablet depends on when you missed the tablet. There is a higher risk of becoming pregnant if you miss a beige tablet at the beginning or end of a pack.

If after taking your missed tablet you have less than 7 days of beige active tablets left in a row, you should finish the active tablets in your pack but skip the white inactive tablets and start a new pack with the beige active tablets corresponding to the correct day of the week.

This is the best way to maintain contraceptive protection. However, you may not have a period until the end of the beige active tablets of the second pack. You may have spotting or breakthrough bleeding on tablet-taking days.

If you have been taking the beige active tablets for less than 7 days and miss a beige active tablet, take the missed tablet as soon as you remember, then go back to taking your medicine as you would normally, even if this means taking two tablets in one day at the same time. In addition, you must also use additional barrier contraceptive precautions (e.g. condoms or a diaphragm) for the next 7 days.

If you have had sexual intercourse in the preceding 7 days, there is a possibility of pregnancy, and you may need emergency contraception. You should discuss this with your doctor or pharmacist.

If you forget to take more than one beige active tablet, seek advice from your doctor or pharmacist about what to do.

If you have had sexual intercourse in the week before missing your tablets, there is a possibility of becoming pregnant. You should discuss this with your doctor or pharmacist.

If you miss a white inactive tablet, you do not need to take them later because they do not contain any active ingredients. However, it is important that you discard the missed white tablet(s) to make sure that the number of days between taking active tablets is not increased as this would increase the risk of pregnancy. Continue with the next tablet at the usual time.

Please see the diagram at the end of this leaflet entitled “Summary of advice if you missed an active tablet more than 12 hours ago”.

Ask your doctor or pharmacist to answer any questions you may have.

If you use too much JULIET®-35 ED

If you think that you have used too much Juliet-35 ED, you may need urgent medical attention.

You should immediately:

  • phone the Poisons Information Centre
    (by calling 13 11 26), or
  • contact your doctor, or
  • go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning. You may need medical attention.

If you take several beige active tablets at once, you may feel sick or vomit or may bleed from the vagina. Even girls who have not yet started to menstruate but have accidentally taken this medicine may experience such bleeding

5. What should I know while using JULIET®-35 ED?

Things you should do

Tell any other doctors, dentists, and pharmacists who treat you that you are taking this medicine.

If you are about to have any blood tests, tell your doctor that you are taking this medicine. It may interfere with the results of some tests.

Have regular check-ups with your doctor. When you are taking Juliet-35 ED, your doctor will tell you to return for regular check-ups, including getting a Cervical Screening Test. Your doctor will advise how often you need a Cervical Screening Test. A Cervical Screening Test can detect abnormal cells lining the cervix. Sometimes abnormal cells can progress to cancer.

If you are about to start on any new medicine, remind your doctor and pharmacist that you are taking Juliet-35 ED.

Stop taking JULIET®-35 ED, call your doctor straight away or go to an Emergency Department at your nearest hospital if you notice following signs:

  • one-sided swelling of the leg and/or foot or along a vein in the leg
  • pain or tenderness in the leg which may be felt only when standing or walking
  • increased warmth in the affected leg; red or discoloured skin on the leg
  • sudden onset of unexplained shortness of breath or rapid breathing
  • sudden coughing or coughing up of blood
  • sharp chest pain or sudden severe pain in the chest which may increase with deep breathing
  • severe light headedness or dizziness
  • rapid or irregular heartbeat
  • sudden pain, swelling and slight blue discoloration of an extremity
  • sudden numbness or weakness of the face, arm or leg, especially on one side of the body
  • sudden trouble walking, dizziness, loss of balance or coordination
  • sudden confusion, slurred speech or aphasia; sudden partial or complete loss of vision, double vision, painless blurring of vision which can progress to loss of vision
  • sudden, severe or prolonged headache with no known cause
  • loss of consciousness or fainting with or without seizure.
  • pain, discomfort, pressure, heaviness, sensation of squeezing or fullness in the chest arm, or below the breastbone
  • discomfort radiating to the back, jaw, throat, arm, stomach
  • feeling of being full, having indigestion or choking
  • sweating, nausea, vomiting
  • extreme weakness and anxiety

If you are going to have surgery, tell the surgeon or anesthetist beforehand that you are taking Juliet-35 ED.
The risk of having blood clots is temporarily increased as a result of major surgery, any surgery to the legs or pelvis, neurosurgery or major trauma. In women who take Juliet-35 ED, the risk may be higher.

In women at risk of prolonged immobilization (including major surgery, any surgery to the legs or pelvis, neurosurgery, or major trauma), your doctor may tell you to stop taking (in the case of elective surgery at least four weeks in advance) and not resume until two weeks after complete remobilization. Another method of contraception should be used to avoid unintentional pregnancy. Your doctor may prescribe other treatment (e.g. treatment for blood clots) if Juliet-35 ED has not been discontinued in advance.

Other risk factors for blood clotting include temporary immobilization including air travel of greater than 4 hours, particularly in women with other risk factors. Consult your doctor if you plan to air travel for greater than 4 hours.

Consult your doctor if you develop high blood pressure while taking Juliet-35 ED – you may be told to stop taking it.

If you become pregnant while taking this medicine, tell your doctor immediately.

If you vomit within 3-4 hours or have severe diarrhoea after taking a beige active tablet, the active ingredients may not have been completely absorbed. This is like missing a tablet. Follow the advice for missed tablets.

If you have unexpected bleeding and it continues, becomes heavy, or occurs again, tell your doctor. When taking these tablets for the first few months, you can have irregular vaginal bleeding (spotting or breakthrough bleeding) between your periods. You may need to use sanitary products, but continue to take your tablets as normal. Irregular vaginal bleeding usually stops once your body has adjusted to Juliet-35 ED, usually after about 3 months.

If you have missed a period, but you have taken all your tablets, it is unlikely that you are pregnant, as long as:

  • you have taken the beige active tablets at the right time
  • you have not been taking medicine(s) that may interfere with Juliet-35 ED.
  • you have not vomited or had severe diarrhea during this cycle.

If this is so, continue to take Juliet-35 ED as usual. If you have any concerns consult your doctor or pharmacist.

If you miss your period twice in a row, you may be pregnant even if you have taken Juliet-35 ED correctly. Stop taking Juliet-35 ED and seek advice from your doctor. You must use a non-hormonal method of contraception, (such as condoms or a diaphragm) until your doctor rules out pregnancy.

Juliet-35 ED will not protect you from HIV-AIDS or any other sexually transmitted infections (STIs), such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, human papilloma virus and syphilis.

To protect yourself from STIs, you will need to use additional barrier contraceptives (e.g. condoms).

Remind any doctor, dentist or pharmacist you visit that you are using Juliet-35 ED.

Things you should not do

You can stop taking Juliet-35 ED at any time.

It is possible that the original condition may recur once Juliet-35 ED is stopped. Do not start taking Juliet-35 ED again without seeing your doctor first.

Do not take Juliet-35 ED to treat any other conditions, unless your doctor tells you to.

Do not give your medicine to anyone else.

Do not stop taking your medicine or change the dosage without checking with your doctor. You may become pregnant if you are not using any other contraceptive and you stop taking Juliet-35 ED, or do not take a tablet every day

Looking after your medicine

  • Keep your tablets in a cool dry place where the temperature stays below 25°C

Keep your tablets in the blister pack until it is time to take them. If you take the tablets out of the pack, they may not keep well.

Follow the instructions in the carton on how to take care of your medicine properly.

Store it in a cool dry place away from moisture, heat or sunlight; for example, do not store it:

  • in the bathroom or near a sink, or
  • in the car or on window sills.

Keep it where young children cannot reach it.

A locked cupboard at least one-and-a-half meters above the ground is a good place to store medicines

When to discard your medicine

If your doctor tells you to stop taking this medicine or the expiry date has passed, ask your pharmacist what to do with any medicine that is left over.

Return any unused medicine to your pharmacist

Getting rid of any unwanted medicine

If you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal.

Do not use this medicine after the expiry date.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking Juliet-35 ED.

This medicine helps most women, but it may have unwanted side effects in some women.

All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical attention if you get some of the side effects.

Do not be alarmed by the following lists of side effects. You may not experience any of them.

Less serious side effects

Less serious side effectsWhat to do
  • nausea
  • stomach pain or discomfort
  • changes in weight
  • headache, including migraines
  • mood changes, including depression
  • breast tenderness or pain
Speak to your doctor if you have any of these less serious side effects and they worry you

Serious side effects

The following list includes very serious but rare side effects. You may need urgent medical attention or hospitalization.

Serious side effectsWhat to do
  • pain in the chest, arm, or below the breastbone
  • pain or discomfort that goes to your back
  • breathlessness and/or difficulty breathing
  • swelling, pain or tenderness of one leg or along a vein in the leg
  • sudden weakness, numbness or bad ‘pins and needles’ of the face, arm or leg, especially on one side of the body
  • sudden trouble walking, dizziness, loss of balance or coordination
  • severe, sudden stomach pains
  • a fainting attack or you collapse
  • unusual headaches or migraines that are worse than usual
  • sudden problems with speaking, seeing or understanding what people are saying to you.

The side effects listed above are possible signs of a blood clot (thrombosis)

  • jaundice (yellowing skin or yellowing eyes)
  • you cough up blood
  • breast lumps
  • unexplained vaginal bleeding
Call your doctor straight away or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Blood clots and Juliet-35 ED

Blood clots may block blood vessels in your body. This type of blood clot is also called thrombosis.

Blood clots sometimes occur in the deep veins of the legs. If a blood clot breaks away from the veins where it has formed, it may reach and block the blood vessels of the lungs, causing pulmonary embolism.

Blood clots can also occur in the blood vessels of the heart (causing a heart attack) or the brain (causing a stroke).

Blood clots are a rare occurrence and can develop whether or not you are taking Juliet-35 ED. They can also happen during pregnancy. The risk of having blood clots is higher in Juliet-35 ED users than in non users, but not as high as during pregnancy.

The risk of a blood clot is highest during the first year of taking Juliet-35 ED for the first time, or after having a break from Juliet-35 ED for 4 weeks or more.

If you notice possible signs of a blood clots, stop taking Juliet-35 ED and consult your doctor immediately. To prevent pregnancy, you must also use additional barrier contraceptive precautions (e.g. condoms or a diaphragm).

If you are concerned about an increased risk of blood clots while on Juliet-35 ED, speak to your doctor.

Cancer and Juliet-35 ED

Juliet-35 ED contains a progestogen and an estrogen hormone, and therefore works similarly to the combined oral contraceptive birth control pill, the Pill.

Breast cancer has been diagnosed slightly more often in women who take the Pill than in women of the same age who do not take the Pill.

This slight increase in the numbers of breast cancer diagnoses gradually disappears during the course of the 10 years after women stop taking the Pill.

It is not known whether the difference is caused by the Pill. It may be that these women were examined more often, so that the breast cancer was noticed earlier.

It is important that you check your breasts regularly and contact your doctor if you feel any lumps.

In rare cases benign liver tumours and, even more rarely, malignant liver tumours have been reported in users of the Pill. These tumours may lead to internal bleeding.

Contact your doctor immediately if you have severe pain in your abdomen.

Cervical cancer has been reported to occur more often in women who have been taking the Pill for a long time. This finding may not be caused by the Pill, but may be related to sexual behavior and other factors.

For high doses (25 mg and above) of cyproterone acetate, an increased risk of a benign brain tumor (meningioma) has been reported. If you are diagnosed with meningioma, your doctor will stop all cyproterone containing products, including Juliet-35 ED as a precautionary measure (see section ‘Do not take Juliet-35 ED’).

Reporting side effects

After you have received medical advice for any side effects that you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What JULIET®-35 ED contains

Active ingredient
(main ingredient)
  • 2 mg of cyproterone acetate
  • 35 micrograms of ethinylestradiol
Other ingredients
(inactive ingredients)
  • lactose monohydrate
  • maize starch
  • povidone
  • magnesium stearate
  • sucrose
  • macrogol 6000
  • calcium carbonate
  • purified talc
  • glycerol
  • titanium dioxide
  • iron oxide yellow
  • glycol montanate
  • purified water

Each white inactive tablet contains:

  • lactose monohydrate
  • maize starch
  • povidone
  • magnesium stearate
  • sucrose
  • macrogol 6000
  • calcium carbonate
  • glycol montanate
  • titanium dioxide
Potential allergensTablets do not contain gluten.
Tablets also do not contain tartrazine or any other azo dyes

Do not take this medicine if you are allergic to any of these ingredients.

What JULIET®-35 ED looks like

Juliet-35 ED active tablets are beige and round.

Juliet-35 ED inactive tablets are white and round.

Juliet-35 ED comes in a box containing either 1 or 3 blister packs. Each blister pack contains 21 beige active tablets and 7 white inactive tablets.

Juliet-35 ED is AUST R 75554.

Who distributes JULIET®-35 ED

Made in Germany for:

Bayer Australia Ltd.
ABN 22 000 138 714
875 Pacific Highway
Pymble NSW 2073

This leaflet was prepared in April 2023.

See TGA website (www.ebs.tga.gov.au) for latest Australian Consumer Medicine Information.

® Registered Trademark of the Bayer group, Germany

©Bayer Australia Ltd

All rights reserved.

  8. SUMMARY OF ADVICE IF YOU MISSED AN ACTIVE TABLET MORE THAN 12 HOURS AGO.

Before missing your tablet, did you take beige active tablets for the previous 7 days?NoDid you have sex in the 7 days before missing the tablet?NoTake the tablet missed AND use extra barrier precaution for 7 days. If there are fewer than 7 beige active tablets left in the pack, finish the beige active tablets and go straight to the beige active tablets of the next pack. This means you skip the white inactive tablets.
YesSee your Doctor or Pharmacist for advice
YesDoes your pack still have 7 active beige tablets in a row to follow?NoTake the tablet you missed AND complete taking the beige active tablets. Skip the white inactive tablets. Start your next pack with beige active tablets.
YesTake the tablet you missed AND complete the pack as normal.

Published by MIMS June 2023

BRAND INFORMATION

Brand name

Juliet-35 ED

Active ingredient

Cyproterone acetate + Ethinylestradiol

Schedule

S4

 

1 Name of Medicine

Cyproterone acetate and ethinylestradiol.

2 Qualitative and Quantitative Composition

Juliet-35 ED contains the synthetic progestogen, cyproterone acetate and the synthetic estrogen, ethinylestradiol.
Each beige active tablet contains cyproterone acetate 2 mg and ethinylestradiol 35 microgram.
Excipients with known effect. Lactose monohydrate.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Tablet, sugar coated.
Juliet-35 ED tablets are available in blister packs of 28 tablets. Each blister contains 21 round beige active tablets followed by 7 round white placebo tablets.

4 Clinical Particulars

4.9 Overdose

There have been no reports of serious deleterious effects from overdose. On the basis of general experience with COCs, symptoms that may occur in case of overdose of beige active tablets are: nausea, vomiting and withdrawal bleeding. Withdrawal bleeding may even occur in girls before menarche, if they have accidentally taken Juliet-35 ED. There are no antidotes and further treatment should be symptomatic.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. There is limited evidence available in the literature suggesting that estrogens may be weakly genotoxic at high doses. Ethinylestradiol was negative in studies for DNA adduct formation in cultured human liver slices and in assays for gene mutations (bacterial or mammalian cells in vitro) and gave equivocal results in assays for chromosomal damage (clastogenic effects were not consistently seen and occurred at high doses).
Cyproterone acetate was negative in a standard battery of genotoxicity studies. However, further tests showed that CPA was capable of producing DNA adducts in hepatocytes in rats, dogs and monkeys in vivo and also in freshly isolated rat and human liver cells in vitro following metabolism by hydroxysteroid sulfotransferases. This DNA adduct formation occurred at exposures that might be expected to occur with the recommended dose regimen for Juliet-35 ED.
CPA increased DNA repair activity in rat and human hepatocytes in vitro. CPA was clastogenic in a female rat liver micronucleus test. Other in vivo consequences of CPA treatment were an increased incidence of focal, possibly preneoplastic, liver lesions in which cellular enzymes were altered in female rats, and an increase of mutation frequency in transgenic rats carrying a bacterial gene as a target for mutations. In all of these positives in vivo tests, hepatocyte proliferation is likely to have contributed to the results being positive. CPA had mitogenic activity towards rat hepatocytes in vitro, but not human hepatocytes.
Carcinogenicity. Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis and liver.
In a long-term carcinogenicity study of CPA in rats, an increased incidence of hepatomas was reported at oral dose levels of 50 mg/kg CPA and above. In mouse (and a second rat) carcinogenicity studies, increases in benign proliferative changes (nodular hyperplasia) in liver cells of female mice and male and female rats were reported at oral doses of 2 mg/kg. Because of shortcomings in these studies (inadequate pharmacokinetic data and the need to reassess the liver pathology), the carcinogenic potential of CPA in animals could not be determined.
The clinical relevance of these findings is presently uncertain. Clinical experience and limited epidemiological data available to date do not appear to have supported an increased incidence of hepatic tumours in humans at the recommended clinical dose of 2 mg/day cyproterone acetate. It should also be borne in mind that sexual steroids can promote the growth of certain hormone dependent tissues and tumours.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

Cyproterone acetate is a white to pale yellow crystalline powder. M.P. 206-213°C.
Cyproterone acetate is very soluble in chloroform and dioxane, freely soluble in acetone and benzene, soluble in ethanol, methanol and ethyl acetate, sparingly soluble in solvent hexane and almost insoluble in water.
Ethinylestradiol is a white to slightly yellowish white crystalline powder. M.P. 181-185°C.
Ethinylestradiol is practically insoluble in water, freely soluble in ethanol (96%) and ether, sparingly soluble in chloroform. It dissolves in dilute alkaline solutions.
Chemical structure. Cyproterone acetate. The chemical name for cyproterone acetate is 6-chloro-17α-hydroxy-1α,2α- methylene-pregna-4,6-diene- 3,20-dione acetate and has the following chemical structure:
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSCYPROT.gif Molecular Formula: C24H29ClO4.
Molecular Mass: 416.96.
Ethinylestradiol. The chemical name for ethinylestradiol is 19-nor-17α-pregna-1,3,5,(10)- triene-20-yne-3, 17β-diol and has the following chemical structure:
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSETHEST.gif Chemical Formula: C20H24O2.
Molecular mass: 296.41.
CAS number. Cyproterone acetate: 427-51-0.
Ethinylestradiol: 57-63-6.

7 Medicine Schedule (Poisons Standard)

S4 - Prescription Only Medicine.

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/JULIETST.gif

References

1. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation. Contracept 2007; 75:344-54.
2. Long-term Active Surveillance Study for Oral contraceptives (LASS), 2nd update report based on study status. May 2009.